What’s Driving Cardiff Oncology Inc (CRDF) Stock’s 16.85% Surge Over the Past Month?

Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on August 9, 2021, with a target price of $20. H.C. Wainwright analysts, in their report published on October 22, 2020, also initiated Buy rating and set a price target of $27 for Cardiff Oncology Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.


Sponsored

Cardiff Oncology Inc (CRDF) Stock Trading Recap

On Tuesday, Cardiff Oncology Inc (CRDF) stock saw a modest uptick, ending the day at $3.12 which represents a slight increase of $0.13 or 4.35% from the prior close of $2.99. The stock opened at $2.98 and touched a low of $2.95 during the day, reaching a high of $3.18. The volume of shares traded was 1.10 million exceeding the average volume of 0.50 million.

CRDF Stock Performance and Moving Averages

In recent trading, Cardiff Oncology Inc (CRDF) stock price has shown some volatility, fluctuating 11.03% over the last five trades and 16.85% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -28.44%, and it has gained 33.33% in the previous three months. Currently, CRDF is trading at 14.12%, 22.03%, and 5.25% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.

As of the latest trading close, CRDF, a Healthcare sector stock, is trading -51.40% below its 52-week high but remains 231.91% above its 52-week low. The Average True Range (ATR) (14 days) of 0.2 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.

Cardiff Oncology Inc’s Profitability and Valuation Ratios

Cardiff Oncology Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -6711.28% and a profit margin of -6147.52%, with a gross margin of -28.44%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.

In terms of valuation, Cardiff Oncology Inc’s market capitalization stands at $145.24 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 216.77, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 2.72, comparing the market value to the company’s book value.

Understanding Insider Trading

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 7.76% of Cardiff Oncology Inc (CRDF)’s shares, while financial institutions hold 26.03%.

Related Posts